

WATSON PHARMACEUTICALS INC  
Form 8-K  
November 05, 2003

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant To Section 13 or 15(d) Of the Securities And Exchange Act Of 1934**

**November 5, 2003**

Date of Report (Date of earliest event reported)

**WATSON PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other Jurisdiction  
of Incorporation)

**0-20045**  
(Commission File Number)

**95-3872914**  
(IRS Employer  
Identification Number)

**311 Bonnie Circle**  
**Corona, California**  
(Address of principal executive  
offices)

**92880**  
(Zip Code)

**(909) 493-5300**  
(Registrant's telephone number, including area code)

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)



**Item 7.** Financial Statements, Pro Forma Financial Information and Exhibits.

c. Exhibits

99.1 News Release for Watson Pharmaceuticals' third quarter 2003 results dated November 5, 2003.

**Item 12.** Results of Operations and Financial Condition.

On November 5, 2003, Watson Pharmaceuticals, Inc. (the Company) issued a news release announcing its financial results for the third quarter ended September 30, 2003. A copy of the Company's news release is attached hereto as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 5, 2003.

WATSON PHARMACEUTICALS, INC.

By: /s/ Charles P. Slacik  
Charles P. Slacik  
Executive Vice President and  
Chief Financial Officer